<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04156750</url>
  </required_header>
  <id_info>
    <org_study_id>17612</org_study_id>
    <secondary_id>J2P-MC-LXBA</secondary_id>
    <nct_id>NCT04156750</nct_id>
  </id_info>
  <brief_title>A Study of LY3556050 in Healthy Participants</brief_title>
  <official_title>Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study With LY3556050 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about the safety of LY3556050 after it is
      given by mouth to healthy participants. Blood tests will be performed to check how much
      LY3556050 gets into the bloodstream and how long the body takes to get rid of it. Each
      enrolled participant will receive multiple doses of LY3556050 or placebo and will remain in
      the study for up to 31 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Anticipated">August 3, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 3, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part A - Parallel design. Part B - Open label design.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Part A - Double-blind. Part B - Open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Final Follow-up (up to Week 9)]</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3556050</measure>
    <time_frame>Baseline through Day 17</time_frame>
    <description>PK: Cmax of LY3556050</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve During 1 Dosing Interval (AUCτ)</measure>
    <time_frame>Baseline through Day 17</time_frame>
    <description>PK: AUCτ of LY3556050</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3556050 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3556050 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iohexol (Part B)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Iohexol given intravenously (IV). (Part B is optional.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin (Part B)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Metformin given orally. (Part B is optional.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3556050+ Iohexol (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iohexol given intravenously (IV) coadministered with oral doses of LY3556050. (Part B is optional.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3556050 + Metformin (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin given orally coadministered with oral doses of LY3556050. (Part B is optional.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3556050</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3556050 (Part A)</arm_group_label>
    <arm_group_label>LY3556050 + Metformin (Part B)</arm_group_label>
    <arm_group_label>LY3556050+ Iohexol (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>Iohexol (Part B)</arm_group_label>
    <arm_group_label>LY3556050+ Iohexol (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3556050 + Metformin (Part B)</arm_group_label>
    <arm_group_label>Metformin (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females of nonchild bearing potential, as determined by medical
             history

          -  Have safety laboratory results within normal references ranges

          -  Weight at least 50 kilograms (kg)

        Exclusion Criteria:

          -  Have known allergies to LY3556050, iodine, metformin and related compounds

          -  Abnormal electrocardiogram (ECG) or blood pressure at screening

          -  Significant history of current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, psychiatric or endocrine disorders

          -  Show evidence of active renal disease with estimated glomerular filtration rate (GFR)
             &lt;90 milliliters per minute per 1.73 meters squared
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>469-513-6727</phone>
    </contact>
    <investigator>
      <last_name>Jeanelle Kam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

